Drug intelligence / Profile preview

GR1401

Development stage: Unknown
Lead developer: Zhixiang Jintai
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral

Overview

GR1401 is a monoclonal antibody currently undergoing a Phase I clinical study. It is being investigated for its tolerability, pharmacokinetics, immunogenicity, safety, and preliminary efficacy in patients diagnosed with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, head and neck cancer, and esophageal cancer. The drug is being developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Beyond the preview

Go deeper on GR1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GR1401.

Explore the full profile